Haematologica 2003 - Supplements

esponse, dose was reduced to 400 mg/day and combined with
dexamethasone (DEX) and/or chemotherapy (CH). All patients,
who discontinued THAL for good response and those who
reduced dose because unacceptable toxicity, relapsed. Adjuvant
biphosphonate therapy was done in all and haematopoietic
growth factors when necessary. We evaluated response using the
following criteria: Complete Response (CR: ≥ 90% paraprotein
reduction, no progression of bone lesions and no anaemia), Major
Response (MjR: ≥ 75% and < 90% paraprotein reduction), Partial
Response (PR: ≥ 50% and < 75% paraprotein reduction), Minor
Response (MnR: ≥ 25% and < 50% paraprotein reduction) and
Stable Disease (SD: